IAPSM’s Position Paper on Pneumococcal Vaccine (PCV) for Adult Immunization in India
Pneumococcal infection among adults is associated with invasive disease and poor outcomes. Pneumococcal vaccine (PCV) introduction has significantly reduced disease burden, invasive disease and reduced the rates of antimicrobial resistance. Of the various vaccines licensed, PCV 13 and PPSV 23 are av...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2024-12-01
|
| Series: | Indian Journal of Community Medicine |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/ijcm.ijcm_739_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841556811743756288 |
|---|---|
| author | Chythra R. Rao Veena G. Kamath Anuradha Nadda Swayam P. Parida Nikita Sharma Kapil Goel Ranjitha S. Shetty Madhur Verma Arvind Kumar Singh Abhisek Mishra Swosti Kiran Lalit Sankhe Madhu Gupta |
| author_facet | Chythra R. Rao Veena G. Kamath Anuradha Nadda Swayam P. Parida Nikita Sharma Kapil Goel Ranjitha S. Shetty Madhur Verma Arvind Kumar Singh Abhisek Mishra Swosti Kiran Lalit Sankhe Madhu Gupta |
| author_sort | Chythra R. Rao |
| collection | DOAJ |
| description | Pneumococcal infection among adults is associated with invasive disease and poor outcomes. Pneumococcal vaccine (PCV) introduction has significantly reduced disease burden, invasive disease and reduced the rates of antimicrobial resistance. Of the various vaccines licensed, PCV 13 and PPSV 23 are available for use in India. Pneumococcal vaccination is suggested for people aged 19–64 years with immunosuppression, chronic cardiac, lung and hepatic disease, impaired splenic function, uncontrolled diabetes mellitus, current smokers, and those abusing alcohol. It is recommended that people >65 years of age are vaccinated with PPSV23. The suggested regimen is to administer PCV13 followed by PPSV23 after one year. The vaccines have minimal side effects and tolerated well. Data on vaccine effectiveness from Indian studies is limited. Hence, documenting population demographics with surveillance on serotype specific pneumococcal disease burden in adults is needed. Following this, studies on safety, immunogenicity, and cost-effectiveness of the available vaccines need to be designed and implemented. It is suggested that in the initial phase, PCV needs to be made available for high-risk population followed by vaccination roll-out for adult population of India. |
| format | Article |
| id | doaj-art-96d9784250364511bfb4a7cc948dd5e7 |
| institution | Kabale University |
| issn | 0970-0218 1998-3581 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Community Medicine |
| spelling | doaj-art-96d9784250364511bfb4a7cc948dd5e72025-01-07T06:06:04ZengWolters Kluwer Medknow PublicationsIndian Journal of Community Medicine0970-02181998-35812024-12-0149Suppl 2S132S13810.4103/ijcm.ijcm_739_24IAPSM’s Position Paper on Pneumococcal Vaccine (PCV) for Adult Immunization in IndiaChythra R. RaoVeena G. KamathAnuradha NaddaSwayam P. ParidaNikita SharmaKapil GoelRanjitha S. ShettyMadhur VermaArvind Kumar SinghAbhisek MishraSwosti KiranLalit SankheMadhu GuptaPneumococcal infection among adults is associated with invasive disease and poor outcomes. Pneumococcal vaccine (PCV) introduction has significantly reduced disease burden, invasive disease and reduced the rates of antimicrobial resistance. Of the various vaccines licensed, PCV 13 and PPSV 23 are available for use in India. Pneumococcal vaccination is suggested for people aged 19–64 years with immunosuppression, chronic cardiac, lung and hepatic disease, impaired splenic function, uncontrolled diabetes mellitus, current smokers, and those abusing alcohol. It is recommended that people >65 years of age are vaccinated with PPSV23. The suggested regimen is to administer PCV13 followed by PPSV23 after one year. The vaccines have minimal side effects and tolerated well. Data on vaccine effectiveness from Indian studies is limited. Hence, documenting population demographics with surveillance on serotype specific pneumococcal disease burden in adults is needed. Following this, studies on safety, immunogenicity, and cost-effectiveness of the available vaccines need to be designed and implemented. It is suggested that in the initial phase, PCV needs to be made available for high-risk population followed by vaccination roll-out for adult population of India.https://journals.lww.com/10.4103/ijcm.ijcm_739_24adult vaccinationpneumococcal diseasepneumococcal vaccinepcv 13ppsv 23 |
| spellingShingle | Chythra R. Rao Veena G. Kamath Anuradha Nadda Swayam P. Parida Nikita Sharma Kapil Goel Ranjitha S. Shetty Madhur Verma Arvind Kumar Singh Abhisek Mishra Swosti Kiran Lalit Sankhe Madhu Gupta IAPSM’s Position Paper on Pneumococcal Vaccine (PCV) for Adult Immunization in India Indian Journal of Community Medicine adult vaccination pneumococcal disease pneumococcal vaccine pcv 13 ppsv 23 |
| title | IAPSM’s Position Paper on Pneumococcal Vaccine (PCV) for Adult Immunization in India |
| title_full | IAPSM’s Position Paper on Pneumococcal Vaccine (PCV) for Adult Immunization in India |
| title_fullStr | IAPSM’s Position Paper on Pneumococcal Vaccine (PCV) for Adult Immunization in India |
| title_full_unstemmed | IAPSM’s Position Paper on Pneumococcal Vaccine (PCV) for Adult Immunization in India |
| title_short | IAPSM’s Position Paper on Pneumococcal Vaccine (PCV) for Adult Immunization in India |
| title_sort | iapsm s position paper on pneumococcal vaccine pcv for adult immunization in india |
| topic | adult vaccination pneumococcal disease pneumococcal vaccine pcv 13 ppsv 23 |
| url | https://journals.lww.com/10.4103/ijcm.ijcm_739_24 |
| work_keys_str_mv | AT chythrarrao iapsmspositionpaperonpneumococcalvaccinepcvforadultimmunizationinindia AT veenagkamath iapsmspositionpaperonpneumococcalvaccinepcvforadultimmunizationinindia AT anuradhanadda iapsmspositionpaperonpneumococcalvaccinepcvforadultimmunizationinindia AT swayampparida iapsmspositionpaperonpneumococcalvaccinepcvforadultimmunizationinindia AT nikitasharma iapsmspositionpaperonpneumococcalvaccinepcvforadultimmunizationinindia AT kapilgoel iapsmspositionpaperonpneumococcalvaccinepcvforadultimmunizationinindia AT ranjithasshetty iapsmspositionpaperonpneumococcalvaccinepcvforadultimmunizationinindia AT madhurverma iapsmspositionpaperonpneumococcalvaccinepcvforadultimmunizationinindia AT arvindkumarsingh iapsmspositionpaperonpneumococcalvaccinepcvforadultimmunizationinindia AT abhisekmishra iapsmspositionpaperonpneumococcalvaccinepcvforadultimmunizationinindia AT swostikiran iapsmspositionpaperonpneumococcalvaccinepcvforadultimmunizationinindia AT lalitsankhe iapsmspositionpaperonpneumococcalvaccinepcvforadultimmunizationinindia AT madhugupta iapsmspositionpaperonpneumococcalvaccinepcvforadultimmunizationinindia |